share_log

NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar...

NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar...

nRx Pharmicals 股價上漲,此前該公司在最近完成的自殺性雙相情感障礙患者臨床試驗中宣佈,與護理比較標準相比,NRX-101 具有統計學上的顯著安全優勢...
Benzinga ·  05/06 22:18

NRx Pharmaceuticals Shares Are Trading Higher After the Company Announced a Statistically Significant Safety Advantage of NRX-101 Compared to the Standard of Care Comparator in Its Recently Completed Clinical Trial in Patients With Suicidal Bipolar Depression and Plans to Seek Accelerated Approval of NRX-101.

nRx Pharmicals在最近完成的針對自殺性雙相抑鬱症患者的臨床試驗中宣佈,與護理比較標準相比,NRX-101 具有統計學上的顯著安全優勢,此後,該公司股價走高,並計劃尋求加速批准 NRX-101。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論